ule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Sheffield Resources Limited

ABN

29 125 811 083

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued Unlisted Options (Options)

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Options each have an exercise price of \$0.65 each and an expiry date of 30 Nov 2023. Exercise of the Options is subject to the terms and conditions of the options set out in Schedule 1 of the Notice of Meeting dated 10 Oct 2019 and approved by shareholders on 19 Nov 2019.

960,000

<sup>+</sup> See chapter 19 for defined terms.

| 4     | <ul> <li>Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?</li> <li>If the additional *securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> </li> </ul> | No. The Options are not quoted. The<br>Options do not entitle the holder to<br>participate in dividends or new issues of<br>securities. However, the Options will be<br>adjusted in the event of a reorganisation<br>or reconstruction of capital. Shares<br>issued on exercise of Options shall rank<br>equally in all respects with the existing<br>fully paid ordinary shares then on issue. |
|-------|---|---|
| _     | logue price or consideration  | NT*1  |
| 5     | Issue price or consideration  | Nil.  |
|       |   |   |
| 6     | Purpose of the issue<br>(If issued as consideration for the<br>acquisition of assets, clearly<br>identify those assets)   | Issued to non-executive directors as set<br>out in Notice of Meeting dated 10 Oct<br>2019.  |
|       |   |   |
| 6a    | Is the entity an <sup>+</sup> eligible entity<br>that has obtained security holder<br>approval under rule 7.1A?<br>If Yes, complete sections 6b – 6h<br><i>in relation to the <sup>+</sup>securities the</i><br><i>subject of this Appendix 3B</i> , and<br>comply with section 6i  | Yes   |
|       |   |   |
| 6b    | The date the security holder<br>resolution under rule 7.1A was<br>passed  | 19 November 2019  |
| 6с    | Number of +securities issued<br>without security holder approval<br>under rule 7.1  | Nil   |
|       |   |   |
| 1.0-  | abapton 10 for defined to me  |   |
| + See | chapter 19 for defined terms.   |   |

- 6d Number of +securities issued Nil with security holder approval under rule 7.1A 6e Number of +securities issued with security holder approval meeting held 19 November 2019) under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of +securities issued Nil under an exception in rule 7.2 6g If +securities issued under rule N/A 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation. 6h If +securities were issued under N/A rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity's remaining See Annexure issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- +Issue dates 7

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

+ See chapter 19 for defined terms.

960,000 (shareholder approval granted at

29 November 2019

|    |  | Number              | +Class                     |
|----|--|---------------------|----------------------------|
| 8  | Number and <sup>+</sup> class of all<br><sup>+</sup> securities quoted on ASX<br>( <i>including</i> the <sup>+</sup> securities in<br>section 2 if applicable) | 308,959,220         | Fully paid ordinary shares |
|    |  | Numeron             | +Class                     |
| 0  | Number and <sup>+</sup> class of all   | Number<br>1,600,000 | +Class<br>Unlisted options |
| 9  | *securities not quoted on ASX<br>( <i>including</i> the *securities in   | 1,000,000           | (\$1.16, 19/03/2021)       |
|    | section 2 if applicable)   | 3,000,000           | Unlisted                   |
|    |  |                     | Performance                |
|    |  |                     | options (\$0.001,          |
|    |  |                     | 08/02/2020)                |
|    |  | 1,300,000           | Unlisted                   |
|    |  |                     | Performance                |
|    |  |                     | Options (\$0.001,          |
|    |  |                     | 24/11/2020)                |
|    |  | 700,000             | Unlisted ESOP              |
|    |  |                     | Options (Series A)         |
|    |  |                     | (\$0.001, 24/11/2020)      |
|    |  | 235,000             | Unlisted ESOP              |
|    |  |                     | Options (Series B)         |
|    |  |                     | (\$0.84, 24/11/2020)       |
|    |  | 1,700,000           | Performance Rights         |
|    |  |                     | (exp. 30/11/2021)          |
|    |  | 312,500             | Performance Rights         |
|    |  |                     | (exp. 1/3/2022)            |
|    |  | 1,541,516           | Performance Rights         |
|    |  |                     | (exp. 26/10/2025)          |
|    |  | 5,784,343           | Performance Rights         |
|    |  |                     | (exp 01/12/2025)           |
|    |  | 960,000             | Unlisted options           |
|    |  | 200,000             | (\$0.65, 30/11/2023)       |
|    |  |                     |                            |
| 10 | Dividend policy (in the case of a trust distribution policy) on the  | N/A                 |                            |

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

he N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2 - Pro rata issue

- Is security holder approval 11 required?
- Is the issue renounceable or non-12 renounceable?
- Ratio in which the <sup>+</sup>securities will 13 be offered
- <sup>+</sup>Class of <sup>+</sup>securities to which the 14 offer relates
- <sup>+</sup>Record date to determine 15 entitlements
- Will holdings different 16 on registers (or subregisters) be aggregated for calculating entitlements?
- Policy for deciding entitlements 17 in relation to fractions
- 18 Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

Closing date for receipt of N/A 19 acceptances or renunciations

Names of any underwriters 20

N/A N/A N/A

N/A

N/A

- Amount of any underwriting fee | N/A 21 or commission
- Names of any brokers to the issue 22

| 2 | N/A |
|---|-----|
|   |     |

N/A

N/A

N/A

N/A

<sup>+</sup> See chapter 19 for defined terms.

- Fee or commission payable to the 23 broker to the issue
- Amount of any handling fee 24 payable to brokers who lodge acceptances or renunciations on behalf of security holders
- If the issue is contingent on 25 security holders' approval, the date of the meeting
- Date entitlement and acceptance 26 form and offer documents will be sent to persons entitled
- If the entity has issued options, 27 and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- Date rights trading will begin (if N/A 28 applicable)
- Date rights trading will end (if N/A 29 applicable)
- How do security holders sell their 30 entitlements in full through a broker?
- How do security holders sell *part* 31 of their entitlements through a broker and accept for the balance?
- How do security holders dispose 32 of their entitlements (except by sale through a broker)?
- +Issue date 33

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A


N/A

04/03/2013 Doc ID 691351713/v1

+ See chapter 19 for defined terms.

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities



#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders
- If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories
   1 1,000
   1,001 5,000
   5,001 10,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000
   100,000<

A copy of any trust deed for the additional +securities

37

<sup>+</sup> See chapter 19 for defined terms.

### Entities that have ticked box 34(b)

| 38 | Number of *securities for which<br>*quotation is sought   |  |
|----|---|--|
| 39 | <sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought   |  |
| 40 | Do the <sup>+</sup> securities rank equally in<br>all respects from the <sup>+</sup> issue date<br>with an existing <sup>+</sup> class of quoted<br><sup>+</sup> securities?  |  |
|    | <ul> <li>If the additional <sup>+</sup>securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> |  |
| 41 | Reason for request for quotation now  |  |
|    | Example: In the case of restricted securities, end of restriction period  |  |
|    | (if issued upon conversion of<br>another <sup>+</sup> security, clearly identify<br>that other <sup>+</sup> security)   |  |

42 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in clause 38)

| Number | +Class |
|--------|--------|
|        |        |
|        |        |
|        |        |
|        |        |
|        |        |
|        |        |

<sup>+</sup> See chapter 19 for defined terms.

#### Quotation agreement

<sup>1</sup> <sup>+</sup>Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
     Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Company secretary)

Date: 29 November 2019

Print name: Mark Di Silvio

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

| Rule 7.1 – Issues exceeding 15% of capital  |   |  |
|---|---|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated  |   |  |
| <i>Insert</i> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue   | 230,471,056   |  |
| <ul> <li>Add the following:</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>   | - 1,016,133<br>- 24,970,812<br>- 1,505,570<br>- 4,781,803<br>- 46,153,846 |  |
| <ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> | Nil   |  |
| <i>Subtract</i> the number of fully paid<br><sup>+</sup> ordinary securities cancelled during that<br>12 month period   | Nil   |  |
| "A"   | 308,899,220   |  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A"  |                                  |  |
|---|----------------------------------|--|
| "B"   | 0.15                             |  |
| <i>Multiply</i> "A" by 0.15   | 46,334,883                       |  |
| Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used   |                                  |  |
| <ul> <li><i>Insert</i> number of <sup>+</sup>equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</li> <li>Under an exception in rule 7.2</li> </ul>   | 60,000 (Share issue 15 Feb 2019) |  |
| Under rule 7.1A   |                                  |  |
| • With security holder approval under rule 7.1 or rule 7.4  |                                  |  |
| <ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> |                                  |  |
| " <b>C</b> "  | 60,000                           |  |
| Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1  |                                  |  |
| "A" x 0.15  | 46,334,883                       |  |
| Note: number must be same as shown in<br>Step 2   |                                  |  |
| Subtract "C"  | 60,000                           |  |
| Note: number must be same as shown in<br>Step 3   |                                  |  |
| <i>Total</i> ["A" x 0.15] – "C"   | 46,274,883                       |  |

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

•

.

•

"E"

annexed

, obtained

| Rule 7.1A – Additional placement capacity for eligible entities<br>Step 1: Calculate "A", the base figure from which the placement capacity<br>is calculated |            |  |
|--|------------|--|
|  |            |  |
| Step 2: Calculate 10% of "A"   |            |  |
| "D"  | 0.10       |  |
| <i>Multiply</i> "A" by 0.10  | 30,889,922 |  |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used   |            |  |
| <i>Insert</i> number of <sup>+</sup> equity securities issued<br>or agreed to be issued in that 12 month<br>period under rule 7.1A                           |            |  |
| Notes:<br>• This applies to equity securities – not just<br>ordinary securities  |            |  |

## Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

0

| "A" x 0.10<br>Note: number must be same as shown in Step<br>2          | 30,889,922  |
|--|---|
| <i>Subtract</i> "E"<br>Note: number must be same as shown in Step<br>3 | 0   |
| <i>Total</i> ["A" x 0.10] – "E"  | 30,889,922<br>Note: this is the remaining placement capacity<br>under rule 7.1A |

<sup>+</sup> See chapter 19 for defined terms.

Include here - if applicable - the securities the

Do not include equity securities issued under

subject of the Appendix 3B to which this form is

rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been

It may be useful to set out issues of securities on

different dates as separate line items